Michal Walczak, CSO, has been invited to Targeted Protein Degradation Summit 2018, Boston, MA, which is the first scientific meeting dedicated entirely to the emerging field of targeted protein degradation. Michal will give a speech about Future Directions for Targeted Protein Degradation, such as expanding the pool of ubiquitin-related enzymes. The forum will bring together all important players from academia, including Craig Crews, an inventor of PROTACTM technology and industry, e.g. AstraZeneca, GSK, Amgen and many more. TPD 2018 will summarize new trends in this rapidly growing technology, with the focus on the rational design of bifunctional molecules and their translation into safe and effective drugs.